Berotralstat May Reduce On-Demand Medication Use in Hereditary Angioedema
Berotralstat may reduce the use of on-demand medications in patients with hereditary angioedema (HAE) who were previously treated with prophylactic therapies.
Hereditary Angioedema
Oral Hereditary Angioedema Treatment Provides Effective Bradykinin-Inhibiting Concentrations
A single dose of PHA-022121, an oral beta-2 antagonist, was associated with effective bradykinin-inhibiting concentrations within 15 minutes of administration in patients with hereditary angioedema.
New Drug Product: Orladeyo
This slideshow shows drug information for Orladeyo. Click here for the complete Orladeyo monograph.
Orladeyo Now Available for Hereditary Angioedema
The oral, once-daily treatment will be shipped to patients with a prescription by specialty pharmacy Optime Care, Inc.
FDA Approves Orladeyo to Prevent Hereditary Angioedema Attacks
Orladeyo works by binding to plasma kallikrein and inhibiting its proteolytic activity.
Berotralstat Improves Quality of Life in Hereditary Angioedema
Patients with hereditary angioedema taking berotralstat prophylactically had improved quality of life.
Lanadelumab Markedly Reduces Hereditary Angioedema Attacks Over 30-Month Period
Lanadelumab was effective for reducing hereditary angioedema attacks at up to 30 weeks of treatment, suggesting the monoclonal antibody is associated with sustained long-term efficacy.
Haegarda Approved for Pediatric Hereditary Angioedema
The expanded approval was based on data from the pivotal phase 3 COMPACT study and the COMPACT open-label extension study.
Berotralstat NDA for Hereditary Angioedema Prophylaxis Submitted to FDA
The New Drug Application (NDA) for berotralstat (BCX7353; BioCryst) for the prevention of hereditary angioedema (HAE) attacks has been submitted to the Food and Drug Administration.
Long-Term Data Show Lanadelumab Effective in Preventing HAE Attacks
This article is part of MPR‘s coverage of the ACAAI 2019 meeting, taking place in Houston, TX. Our staff will report on medical research related to allergies, asthma, and more conducted by experts in the field. Check back regularly for more news from ACAAI 2019. Data from the open-label extension (OLE) portion of the phase…
